Evaluating New Alzheimer's Drugs: Efficacy and Risks

There are now two fully approved drugs on the market that can, sometimes, slow down the progression of Alzheimer's disease. Both have been shown to slow down the mental decline of Alzheimer's by more than 25%. But that's in a group of patients—an individual may do much better, or not be helped at all. NPR Science Correspondent Jon Hamilton has been talking to people who've taken these drugs. Today he has the story of two patients to receive them.

Interested in more human health stories? Contact us at shortwave@npr.org.

Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.

Learn more about sponsor message choices: podcastchoices.com/adchoices

NPR Privacy Policy